

Statistical Analyses 1 for Specificity for Exclusion of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA

Statistical analysis title	Statistical analysis 1- Majority reader		Analysis Type	Non-Inferiority				
			Comment	To determine if gadobutrol-enhanced MRA was non-inferior to unenhanced MRA, using a pre-specified non-inferiority margin of -7.5%.				
Statistical analysis description	The percentage difference was calculated as gadobutrol-enhanced minus unenhanced MRA. In the below table, "n/n" signifies those subjects/segments that were evaluable for the specified category.							
Comparison groups or subject analysis sets	Gadobutrol-Enhanced MRA versus Unenhanced MRA							
Number of subjects in this analysis	(n=457/9321)							
Analysis specification	<i>Pre-specified</i>							
Parameter Estimate								
Parameter type	Other effect estimate: Percentage difference							
Point estimate	8.8							
Confidence interval	Level	Other: 95.1%	Sides	2	Lower limit	7.7	Upper limit	NA*
Variability estimate	Choose an item.			Dispersion Value				

*NA - Not Appropriate, upper intervals were not used in the statistical analysis and were not of interest for the study.

Statistical Analyses 2 for Specificity for Exclusion of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA

Statistical analysis title	Statistical analysis 2- Blinded reader 1		Analysis Type	Non-Inferiority				
			Comment	To determine if gadobutrol-enhanced MRA was non-inferior to unenhanced MRA, using a pre-specified non-inferiority margin of -7.5%.				
Statistical analysis description	The percentage difference was calculated as gadobutrol-enhanced minus unenhanced MRA. In the below table, "n/n" signifies those subjects/segments that were evaluable for the specified category.							
Comparison groups or subject analysis sets	Gadobutrol-Enhanced MRA versus Unenhanced MRA							
Number of subjects in this analysis	(n=457/9321)							
Analysis specification	<i>Pre-specified</i>							
Parameter Estimate								
Parameter type	Other effect estimate: Percentage difference							
Point estimate	30.3							
Confidence interval	Level	Other: 95.1%	Sides	2	Lower limit	28.6	Upper limit	NA*
Variability estimate	Choose an item.			Dispersion Value				

*NA - Not Appropriate, upper intervals were not used in the statistical analysis and were not of interest for the study.

Statistical Analyses 3 for Specificity for Exclusion of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA

Statistical analysis title	Statistical analysis 3 - Blinded reader 2		Analysis Type	Non-Inferiority				
			Comment	To determine if gadobutrol-enhanced MRA was non-inferior to unenhanced MRA, using a pre-specified non-inferiority margin of -7.5%.				
Statistical analysis description	The percentage difference was calculated as gadobutrol-enhanced minus unenhanced MRA. In the below table, "n/n" signifies those subjects/segments that were evaluable for the specified category.							
Comparison groups or subject analysis sets	Gadobutrol-Enhanced MRA versus Unenhanced MRA							
Number of subjects in this analysis	(n=457/9321)							
Analysis specification	<i>Pre-specified</i>							
Parameter Estimate								
Parameter type	Other effect estimate: Percentage difference							
Point estimate	9.7							
Confidence interval	Level	Other: 95.1%	Sides	2	Lower limit	8.5	Upper limit	NA*
Variability estimate	Choose an item.			Dispersion Value				

*NA - Not Appropriate, upper intervals were not used in the statistical analysis and were not of interest for the study.

Statistical Analyses 4 for Specificity for Exclusion of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA

Statistical analysis title	Statistical analysis 4 - Blinded reader 3		Analysis Type	Non-Inferiority				
			Comment	To determine if gadobutrol-enhanced MRA was non-inferior to unenhanced MRA, using a pre-specified non-inferiority margin of -7.5%.				
Statistical analysis description	The percentage difference was calculated as gadobutrol-enhanced minus unenhanced MRA. In the below table, "n/n" signifies those subjects/segments that were evaluable for the specified category.							
Comparison groups or subject analysis sets	Gadobutrol-Enhanced MRA versus Unenhanced MRA							
Number of subjects in this analysis	(n=457/9321)							
Analysis specification	<i>Pre-specified</i>							
Parameter Estimate								
Parameter type	Other effect estimate: Percentage difference							
Point estimate	7.6							
Confidence interval	Level	Other: 95.1%	Sides	2	Lower limit	6.6	Upper limit	NA*
Variability estimate	Choose an item.			Dispersion Value				

*NA - Not Appropriate, upper intervals were not used in the statistical analysis and were not of interest for the study.

Statistical Analyses 5 for Specificity for Exclusion of Clinically Significant Disease Using Gadobutrol-Enhanced MRA and Unenhanced MRA

Statistical analysis title	Statistical analysis 5 - Clinical investigators		Analysis Type	Non-Inferiority				
			Comment	To determine if gadobutrol-enhanced MRA was non-inferior to unenhanced MRA, using a pre-specified non-inferiority margin of -7.5%.				
Statistical analysis description	The percentage difference was calculated as gadobutrol-enhanced minus unenhanced MRA. In the below table, "n/n" signifies those subjects/segments that were evaluable for the specified category.							
Comparison groups or subject analysis sets	Gadobutrol-Enhanced MRA versus Unenhanced MRA							
Number of subjects in this analysis	(n=457/9133)							
Analysis specification	<i>Pre-specified</i>							
Parameter Estimate								
Parameter type	Other effect estimate: Percentage difference							
Point estimate	9.1							
Confidence interval	Level	Other: 95.1%	Sides	2	Lower limit	7.9	Upper limit	NA*
Variability estimate	Choose an item.			Dispersion Value				

*NA - Not Appropriate, upper intervals were not used in the statistical analysis and were not of interest for the study.